Cairo – Mubasher: The Egyptian International Pharmaceutical Industries (EIPICO) logged consolidated net profits of EGP 270.76 million in the first half (H1) of 2021, slightly up from EGP 262.2 million in H1-20.
The pharmaceutical company's sales increased to EGP 1.58 billion in the six-month period ended 30 June from EGP 1.45 billion in the prior-year period, according to a bourse disclosure on Wednesday.
As for standalone business, EIPICO reported net profits of EGP 244.99 million in H1-21, up from EGP 221.7 million in H1-20.
In the first quarter (Q1) of 2021, the company achieved net profits of EGP 178.06 million, down from EGP 189.1 million in Q1-20.
